C WorldWide Group Holding A S Trims Stock Position in Outset Medical, Inc. (NASDAQ:OM)

C WorldWide Group Holding A S cut its holdings in shares of Outset Medical, Inc. (NASDAQ:OM - Free Report) by 93.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 66,666 shares of the company's stock after selling 933,334 shares during the quarter. C WorldWide Group Holding A S owned 1.85% of Outset Medical worth $737,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Two Sigma Securities LLC increased its stake in shares of Outset Medical by 190.0% during the fourth quarter. Two Sigma Securities LLC now owns 42,477 shares of the company's stock worth $47,000 after buying an additional 27,830 shares during the period. XTX Topco Ltd acquired a new position in Outset Medical during the 4th quarter worth approximately $50,000. Squarepoint Ops LLC purchased a new stake in shares of Outset Medical during the 4th quarter worth $174,000. Birchview Capital LP lifted its position in shares of Outset Medical by 3,587.7% during the 4th quarter. Birchview Capital LP now owns 368,766 shares of the company's stock worth $409,000 after purchasing an additional 358,766 shares during the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of Outset Medical by 36.0% during the fourth quarter. Two Sigma Investments LP now owns 488,602 shares of the company's stock worth $542,000 after purchasing an additional 129,334 shares in the last quarter.

Outset Medical Price Performance

OM traded down $0.18 on Friday, hitting $17.42. 319,110 shares of the company were exchanged, compared to its average volume of 156,165. Outset Medical, Inc. has a fifty-two week low of $5.85 and a fifty-two week high of $62.10. The company has a debt-to-equity ratio of 0.57, a quick ratio of 6.74 and a current ratio of 8.37. The firm has a market capitalization of $308.68 million, a P/E ratio of -0.60 and a beta of 2.15. The business's fifty day moving average is $19.29 and its 200 day moving average is $14.36.

Outset Medical (NASDAQ:OM - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($3.66) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($2.69). Outset Medical had a negative return on equity of 143.62% and a negative net margin of 98.74%. The firm had revenue of $29.75 million for the quarter, compared to analysts' expectations of $27.81 million. As a group, sell-side analysts anticipate that Outset Medical, Inc. will post -1.99 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on OM. Wall Street Zen upgraded shares of Outset Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Scotiabank raised Outset Medical to a "strong-buy" rating in a report on Thursday, May 15th. BTIG Research set a $37.00 target price on Outset Medical and gave the company a "buy" rating in a report on Monday. Royal Bank Of Canada restated a "sector perform" rating and set a $21.00 price target (up previously from $14.00) on shares of Outset Medical in a research note on Wednesday, May 21st. Finally, Stifel Nicolaus set a $15.00 price target on Outset Medical in a research report on Friday, March 21st. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $29.50.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.